IL-1α Antibody Reverses Cachexia Muscle Loss
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cachexia, such as nutritional support and steroids, fail to effectively reverse muscle mass loss and improve survival in cancer patients, despite addressing weight loss and appetite issues.
Innovation Solution
Administration of an IL-1α-targeting agent, specifically a monoclonal antibody like MABp1, which binds to interleukin-1α, to ameliorate cachexia symptoms and extend survival by reversing lean body mass loss and improving metabolic abnormalities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If nutritional support is provided to cachectic patients, then body weight can be maintained, but lean muscle mass continues to be lost
Solution Approach 1:
The patent extracts and targets the specific pathological mechanism (IL-1α cytokine) driving muscle mass loss, separating the treatment of weight maintenance from muscle mass preservation. By administering IL-1α-targeting agents, the invention directly addresses the underlying cause of muscle wasting while nutritional support maintains overall body weight.
Solution Approach 2:
The IL-1α-targeting agent acts as an intermediary that blocks the harmful effects of the IL-1α cytokine on muscle tissue. This mediator prevents the cytokine from triggering muscle breakdown, allowing both weight maintenance through nutrition and muscle mass preservation through targeted biological intervention.
2Quantity of substance
If steroids are administered to increase appetite and reverse weight loss, then weight loss is reversed, but muscle mass loss is not reversed
Solution Approach 1:
The invention extracts the specific mechanism of muscle wasting (IL-1α mediated pathway) and targets it directly, rather than using broad-acting steroids that affect appetite but not the specific cytokine pathway causing muscle loss. This selective targeting reverses muscle mass loss while maintaining weight benefits.
Solution Approach 2:
The patent changes the therapeutic parameter from general anti-inflammatory steroids to specific IL-1α-targeting agents, altering the mechanism of action to directly address muscle mass loss while maintaining appetite stimulation effects.
3Quantity of substance
If conventional treatments are used for cachexia, then appetite and weight can be improved, but survival in cancer patients is not extended
Solution Approach 1:
The invention extracts and targets the specific cytokine pathway (IL-1α) that drives both muscle wasting and poor survival outcomes. By blocking this specific pathway, the treatment extends survival in cancer patients while maintaining the benefits of appetite and weight improvement.
Solution Approach 2:
The IL-1α-targeting agent serves as a mediator that blocks the harmful effects of the cytokine on both muscle tissue and overall survival, providing dual benefits of extended life and improved body composition in cancer cachexia.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The IL-1α-targeting agent significantly increases lean body mass and extends survival in cancer patients with cachexia, as demonstrated by improved body composition and prolonged survival duration in clinical trials.
Implementation Method 1
an agent that specifically target IL-1α can improve the symptoms of cachexia... The IL-1α-targeting agent can be an anti-IL-1α Ab such as a anti-IL-1α monoclonal Ab (mAb)
Data Source
AI summary
Administration of an antibody that specifically binds IL-1α is useful for treating cachexia and increasing the lifespan of a subject suffering from cachexia.